RecruitingNCT04539301
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
Sponsor
Nantes University Hospital
Enrollment
2,100 participants
Start Date
Apr 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux
Exclusion Criteria1
- Patients treated with unfractionated heparin or low molecular weight heparin
Interventions
DIAGNOSTIC_TESTEstimated anticoagulant level (conversion factor x anti-Xa activity)
Estimated anticoagulant level (conversion factor x anti-Xa activity)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04539301
Related Trials
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
NCT0680821732 locations
The CONFORM Pivotal Trial
NCT0514779283 locations
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
NCT072275327 locations
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT0645509846 locations
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698127 locations